Literature DB >> 1573283

A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities.

O N Ozes1, Z Reiter, S Klein, L M Blatt, M W Taylor.   

Abstract

The antiviral, antiproliferative, and natural killer (NK) cell activation by recombinant human interferon-consensus (IFN-Con1) has been compared with that of two other type I IFNs: IFN-alpha 2a (Roferon) and IFN-alpha 2b (Intron A). The specific activity (antiviral units/mg) of IFN-Con1 was 10-fold higher than that of the other two IFNs in the vesicular stomatitis virus (VSV)-HeLa antiviral assay. The antiproliferative activity on a molar basis of IFN-Con1 on Daudi cells and Eskol (a human leukemic hairy cell-like cell line) was significantly greater than that of IFN-alpha 2a and IFN-alpha 2b. IFN-Con1 also enhanced or induced NK cell killing of target cells to a greater extent than that of IFN-alpha 2a and IFN-alpha 2b. However, on antiviral unit basis, the activities were similar. These results would suggest that IFN-Con1 may be more effective at lower protein concentrations in clinical applications than other available IFNs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1573283     DOI: 10.1089/jir.1992.12.55

Source DB:  PubMed          Journal:  J Interferon Res        ISSN: 0197-8357


  27 in total

1.  Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study.

Authors:  Helen S Yee; Sue L Currie; Kathryn Tortorice; Myrna Cozen; Hui Shen; Summer Chapman; Fran Cunningham; Alexander Monto
Journal:  Dig Dis Sci       Date:  2011-06-02       Impact factor: 3.199

Review 2.  Cytokine-receptor interactions as drug targets.

Authors:  Gideon Schreiber; Mark R Walter
Journal:  Curr Opin Chem Biol       Date:  2010-07-07       Impact factor: 8.822

3.  Randomized controlled trial of consensus interferon with or without zinc for chronic hepatitis C patients with genotype 2.

Authors:  Hideyuki Suzuki; Ken Sato; Hitoshi Takagi; Daisuke Kanda; Naondo Sohara; Satoru Kakizaki; Hiroaki Nakajima; Toshiyuki Otsuka; Takeaki Nagamine; Masatomo Mori
Journal:  World J Gastroenterol       Date:  2006-02-14       Impact factor: 5.742

4.  Consensus interferon used to treat prior partial-responders to pegylated interferon plus ribavirin.

Authors:  Christopher M Moore; Magdalena George; David H Van Thiel
Journal:  Dig Dis Sci       Date:  2011-08-31       Impact factor: 3.199

5.  Update on the Use of Consensus Interferon in Difficult-to-Treat Hepatitis C Patients: A Review of Selected Posters From Digestive Disease Week May 20-25, 2006 Los Angeles, Calif.With commentary by:Fred Poordad, MDCedars-Sinai Medical CenterLos Angeles, Calif.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-08

6.  The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients.

Authors:  Tarek Hassanein; Mitchell L Shiffman; Nizar N Zein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-06

7.  Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.

Authors:  Marlena M Westcott; Jingfang Liu; Karishma Rajani; Ralph D'Agostino; Douglas S Lyles; Mercedes Porosnicu
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

Review 8.  IFN-α subtypes: distinct biological activities in anti-viral therapy.

Authors:  K Gibbert; J F Schlaak; D Yang; U Dittmer
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

9.  Antiviral potency analysis and functional comparison of consensus interferon, interferon-alpha2a and pegylated interferon-alpha2b against hepatitis C virus infection.

Authors:  Andrea K Erickson; Scott Seiwert; Michael Gale
Journal:  Antivir Ther       Date:  2008

10.  Comparison of retroviral p15E-related factors and interferon alpha in head and neck cancer.

Authors:  P J Simons; R A Oostendorp; M P Tas; H A Drexhage
Journal:  Cancer Immunol Immunother       Date:  1994-03       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.